Collaboration brings AI Nose to the edge, advancing intelligent sensing and industrial sustainability
Partnership taps ~$60 billion edge AI market, expanding global industrial channels and accelerating AI Nose commercialization
SAN DIEGO, CALIFORNIA / ACCESS Newswire / October 20, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (“Ainos” or the “Company”), a leader in AI-powered scent digitization, today announced that Water Tower Research (“WTR”) has published a report highlighting Ainos’ strategic partnership with NEXCOM International Co., Ltd. (“NEXCOM”), a Taiwan-based pioneer in industrial computing and edge AI solutions. The collaboration marks Ainos’ sixth industrial partnership in 2025, further strengthening its commercial ecosystem centered on the Company’s proprietary AI Nose platform.
Key Highlights from the Report:
Strategic alliance positions Ainos at the forefront of edge AI: Ainos’ partnership with NEXCOM strengthens AI Nose’s presence in the rapidly expanding edge AI computing sector, one of the most transformative frontiers in modern technology. NEXCOM, an NVIDIA ecosystem partner for the Jetson platform, operates across six global business units in the U.S., Taiwan, and China, spanning industrial automation, robotics, intelligent transportation, smart city, and healthcare.
AI Nose integration to elevate industrial efficiency and real-time intelligence: Ainos will integrate its scent-based edge AI solution, powered by AI Nose and smell language model (SLM), into NEXCOM’s edge AI and automation systems, enabling real-time environmental sensing, intelligent monitoring, and predictive maintenance across industrial and manufacturing operations-improving sustainability operations for NEXCOM’s industrial clients. By processing olfactory data locally at the edge instead of in the cloud, the system can reduce latency, safeguard data privacy, and deliver instant actionable insights for mission-critical applications.
Expanding reach through NEXCOM’s global network: Leveraging NEXCOM’s network of 117 partners across 50 countries, Ainos will gain exposure to a significant industrial customer base and potential new distribution channels that could expand SmellTech-as-a-Service commercialization. The partnership also opens synergies between NEXCOM’s edge AI computing platforms and robot controllers and Ainos’ Smell ID dataset, further reinforcing Ainos’ leadership in digital olfaction and intelligent sensing.
Edge AI emerges as a powerful global growth engine: The edge AI market is projected to reach $57-$66 billion by 2030, growing at over 20% compound annual growth rate (“CAGR”), driven by the proliferation of IoT devices, the rollout of 5G networks, and demand for real-time data processing and enhanced privacy across multiple industries. AI Nose is strategically positioned at the intersection of MEMS technology, quantum sensing, and advanced AI algorithms, forming the foundation for a new class of intelligent, context-aware IoT systems that can sense, analyze, and respond in real time.
“Ainos continues to build strong execution momentum toward AI Nose’s commercial launch in 2026,” said Eddy Tsai, Chairman, President, and CEO of Ainos, Inc. “NEXCOM joins a growing lineup of industrial partners that includes global leaders in semiconductors, automation, and robotics-each helping us validate and deploy SmellTech in high-value applications. Together, we’re transforming factory intelligence by bringing scent-based sensing to the edge, turning real-world air data into actionable insights that improve uptime, safety, and sustainability.”
Read the Full Water Tower Research Report Here: https://www.watertowerresearch.com/doc?docID=UR_AIMD_10162025
About Ainos, Inc.
Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of “AI” and “Nose,” is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Feifei Shen
[email protected]
SOURCE: Ainos, Inc.
